Generalized Anxiety Disorder Clinical Trials 2023

What are the top hospitals conducting generalized anxiety disorder research?

When it comes to advancing the understanding and treatment of generalized anxiety disorder (GAD), several top hospitals are leading the way. In Boston, Massachusetts General Hospital is at the forefront with eight ongoing clinical trials dedicated to GAD. With a remarkable history of 31 completed trials since their first recorded investigation in 2003, this esteemed institution continues to push boundaries in anxiety research. Across the border in Toronto, Canada's own Toronto Western Hospital has two active GAD trials under its belt. Despite being relatively new to GAD research, having only started their first trial in 2023, this hospital is already making significant contributions.

Moving southwest to Cincinnati, Ohio, the University of Cincinnati is also actively involved in furthering our understanding of GAD through two ongoing clinical trials. Since embarking on their inaugural study in 2013, they have conducted three total trials on this complex condition. Similarly invested in combating GAD is Kingston Health Sciences Centre located in Kingston, Canada—another facility conducting two active clinical trials for GAD patients. Their journey into exploring treatment options for anxiety disorders began back in 2009 when they embarked on their first recorded trial.

Notably contributing from Houston, Texas is Baylor College of Medicine—an influential institution that currently has two active clinical trials targeting generalized anxiety disorder. Having initiated their first recorded trial over a decade ago in 2008 and completing eleven investigations overall since then shows unwavering dedication towards improving outcomes for individuals struggling with excessive worry and fear.

These notable hospitals serve as beacons of hope for those experiencing the debilitating effects of generalized anxiety disorder worldwide. Through cutting-edge research and innovative treatments provided by these institutions across different locations such as Boston or even internationally like Toronto; advancements are made every day towards alleviating symptoms while enhancing quality-of-life . With each study conducted comes an opportunity for breakthroughs that can revolutionize how we approach mental health challenges

Which are the best cities for generalized anxiety disorder clinical trials?

When it comes to clinical trials for generalized anxiety disorder, several cities are at the forefront of research and innovation. Boston, Massachusetts leads with 16 active trials investigating treatments like Cannabidiol, Buspirone, and QUIT. Houston, Texas follows closely behind with 8 ongoing studies focusing on interventions such as iTCBT-I and Cognitive Behavioral Teletherapy LTA. Los Angeles, California also plays a significant role in this field with 6 active trials exploring strategies like cognitive behavioral therapy combined with benzodiazepine tapering and medication options like Fluoxetine. These cities offer individuals struggling with generalized anxiety disorder access to cutting-edge clinical trials that may revolutionize treatment approaches and improve their quality of life.

Which are the top treatments for generalized anxiety disorder being explored in clinical trials?

Generalized anxiety disorder is a challenging condition, but clinical trials offer hope in exploring new treatments. Two top contenders are cannabidiol and buspirone. Cannabidiol, introduced in 2020, has been the focus of two active trials and is part of five all-time studies for generalized anxiety disorder. Buspirone, on the other hand, made its debut in 2011 and has also garnered attention with two ongoing trials and six total studies dedicated to tackling this condition. These innovative approaches bring potential relief to individuals grappling with generalized anxiety disorder as researchers strive to find effective solutions through rigorous scientific investigation.

What are the most recent clinical trials for generalized anxiety disorder?

Recent clinical trials offer hope for individuals suffering from generalized anxiety disorder. Inositol, a potential treatment for this condition, has shown promise in both Phase 1 and Phase 2 trials conducted as early as September 2023. Another study examined the effects of ABBV-932 specifically on generalized anxiety disorder patients during its Phase 1 trial, which became available in August 2023. Additionally, cannabidiol, a compound derived from cannabis plants, is being investigated in a Phase 4 trial that began in April 2023. Furthermore, endotoxin has been evaluated through a Phase 1 trial starting March 2023 to assess its impact on generalized anxiety disorder symptoms. Lastly, psychotherapy remains an important avenue of research with ongoing investigations into its effectiveness through a Phase 2 trial initiated in April 2022. With these advancements underway, there is renewed optimism for improved management and relief from the burdens of generalized anxiety disorder.

What generalized anxiety disorder clinical trials were recently completed?

Several noteworthy clinical trials for generalized anxiety disorder have recently concluded, signaling progress in the search for effective treatments. In May 2022, Receptor Life Sciences finished a trial investigating Low dose RLS103 as a potential therapeutic option. Similarly, Bionomics Limited completed their study on the efficacy of 225 mg BNC210 in February 2022. Another significant development came from VistaGen Therapeutics, Inc., which wrapped up their PH94B Nasal Spray trial in May 2021. These advancements shed light on ongoing efforts to address and manage generalized anxiety disorder, offering hope to individuals living with this condition.